Avocatin B Protects Against Lipotoxicity and Improves Insulin Sensitivity in Diet-Induced Obesity

Area of Science:

• Biochemistry
• Metabolic Diseases
• Pharmacology

Background:

• Diet-induced obesity (DIO) and lipotoxicity present significant health challenges.
• Current therapeutic agents for these conditions are limited in efficacy and safety.
• Fatty acid oxidation (FAO) is a key metabolic pathway implicated in obesity and related pathologies.

Purpose of the Study:

• To evaluate the effects of avocatin B (AvoB), an avocado-derived FAO inhibitor, on glucose and lipid metabolism.
• To assess the efficacy of AvoB in preclinical models of DIO and in vitro models of lipotoxicity.
• To determine the safety of oral AvoB consumption in humans.

Main Methods:

• Mice were fed a high-fat diet (HFD) and subsequently treated with AvoB or vehicle.
• In vitro studies utilized pancreatic β-islet cells and C2C12 myotubes to assess AvoB's effects on lipotoxicity.
• A randomized, double-blind, placebo-controlled clinical trial evaluated AvoB safety in healthy human participants.

Main Results:

• AvoB administration improved glucose tolerance, glucose utilization, and insulin sensitivity in DIO mice.
• In vitro, AvoB inhibited FAO, increased glucose oxidation, reduced mitochondrial reactive oxygen species, and enhanced insulin responsiveness and secretion.
• Human clinical trials indicated that AvoB was well-tolerated at doses up to 200 mg/day for 60 days, with no dose-limiting toxicity.

Conclusions:

• AvoB demonstrates significant potential as a therapeutic agent for metabolic disorders associated with obesity and lipotoxicity.
• Its mechanism of action, involving FAO inhibition, coupled with a favorable safety profile, underscores its clinical importance.
• AvoB represents a promising nutritional and therapeutic compound for managing metabolic health.